Does the media prefer EPRX or COYA?

In the previous week, Coya Therapeutics had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Coya Therapeutics and 7 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.25 beat Coya Therapeutics' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LRMR or COYA?

In the previous week, Larimar Therapeutics had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 10 mentions for Larimar Therapeutics and 8 mentions for Coya Therapeutics. Larimar Therapeutics' average media sentiment score of 0.43 beat Coya Therapeutics' score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, COYA or OCGN?

Coya Therapeutics has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coya Therapeutics $7.95M 14.16 -$21.23M -$1.15 N/A Ocugen $4.41M 105.35 -$67.85M -$0.26 N/A

Is COYA or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Coya Therapeutics -266.10% -55.86% -48.86% Ocugen N/A -127,987.80% -115.95%

Does the media favor COYA or OCGN?

In the previous week, Ocugen had 22 more articles in the media than Coya Therapeutics. MarketBeat recorded 30 mentions for Ocugen and 8 mentions for Coya Therapeutics. Ocugen's average media sentiment score of 0.02 beat Coya Therapeutics' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor COYA or PBYI?

In the previous week, Puma Biotechnology had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 11 mentions for Puma Biotechnology and 8 mentions for Coya Therapeutics. Puma Biotechnology's average media sentiment score of 0.70 beat Coya Therapeutics' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XFOR or COYA?

In the previous week, X4 Pharmaceuticals had 6 more articles in the media than Coya Therapeutics. MarketBeat recorded 14 mentions for X4 Pharmaceuticals and 8 mentions for Coya Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.54 beat Coya Therapeutics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Coya Therapeutics (COYA) Competitors

$4.80 +0.16 (+3.45%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.02 (+0.48%)

As of 08/11/2026 07:57 PM Eastern

Compare

COYA vs. EPRX, LRMR, OCGN, PBYI, and XFOR

Should you buy Coya Therapeutics stock or one of its competitors? Coya Therapeutics's main competitors and comparable companies include Eupraxia Pharmaceuticals (EPRX), Larimar Therapeutics (LRMR), Ocugen (OCGN), Puma Biotechnology (PBYI), and X4 Pharmaceuticals (XFOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coya Therapeutics compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Eupraxia Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eupraxia Pharmaceuticals presently has a consensus price target of $18.00, indicating a potential upside of 168.66%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 219.44%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Coya Therapeutics	$7.95M	14.16	-$21.23M	-$1.15	N/A

In the previous week, Coya Therapeutics had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Coya Therapeutics and 7 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.25 beat Coya Therapeutics' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Coya Therapeutics beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Larimar Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Coya Therapeutics has higher revenue and earnings than Larimar Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Coya Therapeutics	$7.95M	14.16	-$21.23M	-$1.15	N/A

Larimar Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, Larimar Therapeutics had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 10 mentions for Larimar Therapeutics and 8 mentions for Coya Therapeutics. Larimar Therapeutics' average media sentiment score of 0.43 beat Coya Therapeutics' score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Larimar Therapeutics currently has a consensus price target of $12.57, indicating a potential upside of 191.68%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 219.44%. Given Coya Therapeutics' higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Larimar Therapeutics beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Ocugen?

Coya Therapeutics (NASDAQ:COYA) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Ocugen has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Ocugen	N/A	-127,987.80%	-115.95%

Coya Therapeutics has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.16	-$21.23M	-$1.15	N/A
Ocugen	$4.41M	105.35	-$67.85M	-$0.26	N/A

In the previous week, Ocugen had 22 more articles in the media than Coya Therapeutics. MarketBeat recorded 30 mentions for Ocugen and 8 mentions for Coya Therapeutics. Ocugen's average media sentiment score of 0.02 beat Coya Therapeutics' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 219.44%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 593.43%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Coya Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Summary

Coya Therapeutics beats Ocugen on 9 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Puma Biotechnology?

Coya Therapeutics (NASDAQ:COYA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Puma Biotechnology has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.16	-$21.23M	-$1.15	N/A
Puma Biotechnology	$228.40M	1.98	$31.11M	$0.52	16.87

Puma Biotechnology has a net margin of 11.50% compared to Coya Therapeutics' net margin of -266.10%. Puma Biotechnology's return on equity of 21.34% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Puma Biotechnology	11.50%	21.34%	13.04%

In the previous week, Puma Biotechnology had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 11 mentions for Puma Biotechnology and 8 mentions for Coya Therapeutics. Puma Biotechnology's average media sentiment score of 0.70 beat Coya Therapeutics' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Coya Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Coya Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 219.44%. Puma Biotechnology has a consensus price target of $6.00, suggesting a potential downside of 31.58%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Coya Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats Coya Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

X4 Pharmaceuticals currently has a consensus target price of $9.70, indicating a potential upside of 126.64%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 219.44%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. Coya Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$15.85M	25.47	-$79.20M	-$1.20	N/A
Coya Therapeutics	$7.95M	14.16	-$21.23M	-$1.15	N/A

X4 Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Coya Therapeutics has a net margin of -266.10% compared to X4 Pharmaceuticals' net margin of -568.80%. Coya Therapeutics' return on equity of -55.86% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-64.95%	-37.33%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

In the previous week, X4 Pharmaceuticals had 6 more articles in the media than Coya Therapeutics. MarketBeat recorded 14 mentions for X4 Pharmaceuticals and 8 mentions for Coya Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.54 beat Coya Therapeutics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Coya Therapeutics beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$108.84M	$3.71B	$7.08B	$12.96B
Dividend Yield	N/A	3.76%	2.57%	10.34%
P/E Ratio	-4.17	10.37	268.43	25.05
Price / Sales	14.16	1,285.89	596.97	89.39
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	2.33	17.98	13.21	6.18
Net Income	-$21.23M	-$13.23M	$3.44B	$347.05M
7 Day Performance	5.49%	3.20%	2.09%	1.25%
1 Month Performance	-8.75%	-1.17%	-0.23%	-0.64%
1 Year Performance	-21.70%	59.41%	70.30%	20.12%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	1.7761 of 5 stars	$4.80 +3.4%	$15.33 +219.4%	-22.0%	$108.84M	$7.95M	N/A	6	News Coverage Earnings Report
EPRX Eupraxia Pharmaceuticals	2.1885 of 5 stars	$6.74 +1.2%	$18.00 +167.1%	+25.9%	$437.59M	N/A	N/A	29	News Coverage Earnings Report Gap Up
LRMR Larimar Therapeutics	3.8735 of 5 stars	$4.12 -2.0%	$12.57 +205.5%	+14.0%	$429.54M	N/A	N/A	30	Upcoming Earnings
OCGN Ocugen	2.118 of 5 stars	$1.27 +2.0%	$9.50 +651.0%	+39.7%	$428.97M	$4.41M	N/A	80	Trending News Earnings Report Analyst Revision
PBYI Puma Biotechnology	1.3835 of 5 stars	$8.44 +3.9%	N/A	+80.8%	$426.29M	$228.40M	17.45	200	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. EPRX, LRMR, OCGN, PBYI, and XFOR

How does Coya Therapeutics compare to Eupraxia Pharmaceuticals?

Summary

How does Coya Therapeutics compare to Larimar Therapeutics?

Summary

How does Coya Therapeutics compare to Ocugen?

Summary

How does Coya Therapeutics compare to Puma Biotechnology?

Summary

How does Coya Therapeutics compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. EPRX, LRMR, OCGN, PBYI, and XFOR

How does Coya Therapeutics compare to Eupraxia Pharmaceuticals?

Is EPRX or COYA more profitable?

Which has more risk & volatility, EPRX or COYA?

Do institutionals & insiders have more ownership in EPRX or COYA?

Do analysts recommend EPRX or COYA?

Which has stronger earnings & valuation, EPRX or COYA?

Does the media prefer EPRX or COYA?

Summary

How does Coya Therapeutics compare to Larimar Therapeutics?

Is LRMR or COYA more profitable?

Which has better valuation and earnings, LRMR or COYA?

Which has more volatility & risk, LRMR or COYA?

Does the media favor LRMR or COYA?

Do institutionals & insiders have more ownership in LRMR or COYA?

Do analysts rate LRMR or COYA?

Summary

How does Coya Therapeutics compare to Ocugen?

Is COYA or OCGN more profitable?

Which has stronger earnings and valuation, COYA or OCGN?

Does the media favor COYA or OCGN?

Do analysts recommend COYA or OCGN?

Do insiders and institutionals believe in COYA or OCGN?

Which has more risk & volatility, COYA or OCGN?

Summary

How does Coya Therapeutics compare to Puma Biotechnology?

Which has higher earnings and valuation, COYA or PBYI?

Is COYA or PBYI more profitable?

Does the media favor COYA or PBYI?

Do institutionals and insiders hold more shares of COYA or PBYI?

Which has more risk and volatility, COYA or PBYI?

Do analysts rate COYA or PBYI?

Summary

How does Coya Therapeutics compare to X4 Pharmaceuticals?

Do insiders and institutionals believe in XFOR or COYA?

Do analysts prefer XFOR or COYA?

Which has higher earnings & valuation, XFOR or COYA?

Which has more volatility and risk, XFOR or COYA?

Is XFOR or COYA more profitable?

Does the media refer more to XFOR or COYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools